A Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) With Neratinib in Women With Metastatic HER2-Positive Breast Cancer



Status:Recruiting
Conditions:Breast Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:3/13/2019
Start Date:August 2014
End Date:November 2019
Contact:Diana Gosik, RN, BSN
Email:diana.gosik@nsabp.org
Phone:412-339-5333

Use our guide to learn which trials are right for you!

A Phase Ib/II Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) With Neratinib in Women With Metastatic HER2-Positive Breast Cancer

This study is being done for the following reasons:

- The study has two parts. The purpose of the first part (Phase I) of the study is to find
out the highest dose of neratinib that can be given safely with T-DM1.

- The purpose of the second part of the study (Phase II) is to find out whether the dose
of neratinib with T-DM1 determined in Phase I will keep breast cancer from getting worse
for a period of time.

- In order to learn more about study therapy levels in blood and discover genetic and
protein changes associated with cancer, the study includes special research tests using
samples from blood and from breast tumor. Blood samples will be collected before study
treatment, once during treatment, and after study treatment stops.

- In the optional part of this study, three biopsies will be performed to obtain fresh
tumor samples from an area where your cancer has spread.

The FB-10 study is designed as an open label, single arm, Phase Ib/II study with a
dose-escalation phase and an expanded cohort (phase II) to evaluate the combination of
trastuzumab emtansine (T-DM1) with neratinib in women with metastatic, HER2-positive breast
cancer. The primary aim of the phase Ib portion of this study is to determine the safety and
tolerability of the two-drug combination. The primary aim of the phase II portion is to
demonstrate efficacy.

Patients will receive concurrent therapy with T-DM1 (3.6 mg/kg IV) on Day 1 of a 3-week (21
day) cycle and neratinib as a continuous daily oral dose. The neratinib dose-escalation will
include 4 dose levels (120 mg, 160 mg, 200 mg, and 240 mg). At the recommended phase II dose
(RP2D) of the T-DM1 and neratinib combination, up to 39 additional patients will be treated.

The sample size of the phase I portion of the study will be between 2 and 24 patients. The
sample size of the Phase II portion will be 42 patients. Approximately 6 patients at the
Phase I RP2D level will be included in the Phase II portion. The total study enrollment will
be a maximum of 63 patients. Accrual is expected to occur over 16 months.

Submission of diagnostic tumor samples and blood samples for FB-10 correlative science
studies will be a study requirement for all patients. Blood samples will be collected at
baseline, at Cycle 2, Day 1, and at progression. Blood samples for pharmacokinetic (PK)
determination will be collected at Phase 1 sites from consenting patients at various time
points during the first 24 hours of study therapy (Cycle 1, Days 1 and 2).

An optional tumor biopsy will be procured from consenting patients from an accessible site of
metastasis before study dose level assignment (after the patient has signed the consent form
and has been screened for eligibility), after Cycle 1 of treatment, and at the time of
disease progression.

Inclusion Criteria:

- The ECOG performance status must be less than or equal to 2.

- Patients must have the ability to swallow oral medication.

- Patients must have histologic or cytologic confirmation of the diagnosis of invasive
adenocarcinoma of the breast.

- Patients must have had anti-HER2 based therapy with pertuzumab and trastuzumab for
neoadjuvant therapy, adjuvant therapy or with first line therapy for metastatic
disease (which may include trastuzumab and pertuzumab either sequentially or in
combination).

- There must be documentation that the patient has evidence of measurable metastatic
breast cancer that is accessible to biopsy at study entry.

- Patients must have estrogen receptor (ER) analysis performed prior to study entry. If
ER analysis is negative, then progesterone receptor (PgR) analysis must also be
performed. (Patients are eligible with either hormone receptor-positive or hormone
receptor-negative tumors.)

- Breast cancer must be determined by local testing to be human epidermal growth factor
receptor 2 (HER2)-positive prior to study entry using American Society of Clinical
Oncology (ASCO) - College of American Pathologists (CAP) HER2 test guidelines.

- At the time of study entry, blood counts performed within 4 weeks prior to study entry
must meet the following criteria:

- absolute neutrophil count (ANC) must be greater than or equal to 1000/mm3;

- platelet count must be greater than or equal to 100,000/mm3; and

- hemoglobin must be greater than or equal to 9 g/dL. (Note: Patient must have
discontinued growth factors greater than or equal to two weeks prior to entry
labs.)

- The following criteria for evidence of adequate hepatic function performed within 4
weeks prior to study entry must be met:

- Total bilirubin must be less than or equal to 1.5 x upper limit of normal (ULN),
and

- aspartate aminotransferase (AST) and alanine aminotransferase (ALT) must be less
than or equal to 1.5 x ULN for the lab or less than or equal to 5 x ULN if liver
metastasis.

- Serum creatinine performed within 4 weeks prior to study entry must be less than or
equal to 1.5 x ULN for the lab.

- The left ventricular ejection fraction (LVEF) assessment by 2-D echocardiogram or
multi-gated acquisition (MUGA) scan performed within 90 days prior to study entry must
be greater than or equal to 50% regardless of the facility's lower limit of normal
(LLN).

- Patients with reproductive potential must agree to use an effective non-hormonal
method of contraception during therapy, and for at least 7 months after the last dose
of study therapy.

Exclusion Criteria

- Previous therapy with T-DM1 or any HER2 tyrosine kinase inhibitor (TKI) including
neratinib for any malignancy.

- Symptomatic brain metastases or brain metastases requiring chronic steroids to control
symptoms.

- Active hepatitis B or hepatitis C with abnormal liver function tests; HIV positive
patients receiving antivirals.

- Lung disease resulting in dyspnea at rest.

- Active infection or chronic infection requiring chronic suppressive antibiotics.

- Malabsorption syndrome, ulcerative colitis, inflammatory bowel disease, resection of
the stomach or small bowel, or other disease or condition significantly affecting
gastrointestinal function.

- Persistent greater than or equal to grade 2 diarrhea regardless of etiology.

- Conditions that would prohibit intermittent administration of corticosteroids for
T-DM1 premedication.

- Chronic daily treatment with corticosteroids with a dose of greater than or equal to
10 mg/day methylprednisolone equivalent (excluding inhaled steroids).

- Uncontrolled hypertension defined as a systolic BP greater than 150 mmHg or diastolic
BP greater than 90 mmHg, with or without anti-hypertensive medications. (Patients with
hypertension that is well controlled on medication are eligible.)

- Cardiac disease (history of and/or active disease) that would preclude the use of any
of the drugs included in the treatment regimen. This includes but is not confined to:

- Active cardiac disease: symptomatic angina pectoris within the past 90 days that
required the initiation of or increase in anti-anginal medication or other
intervention; ventricular arrhythmias except for benign premature ventricular
contractions; supraventricular and nodal arrhythmias requiring a pacemaker or not
controlled with medication; conduction abnormality requiring a pacemaker;
valvular disease with documented compromise in cardiac function; and symptomatic
pericarditis

- History of cardiac disease: myocardial infarction documented by elevated cardiac
enzymes or persistent regional wall abnormalities on assessment of left
ventricular (LV) function; history of documented congestive heart failure (CHF);
and documented cardiomyopathy

- Other nonmalignant systemic disease that would preclude the patient from receiving
study treatment or would prevent required follow up.

- Pregnancy or lactation at the time of study entry. (Note: Pregnancy testing should be
performed within 14 days prior to study entry according to institutional standards for
women of childbearing potential.)

- The investigator should assess the patient to determine if she has any psychiatric or
addictive disorder or other condition that, in the opinion of the investigator, would
preclude her from meeting the study requirements.

- Use of any investigational agent within 4 weeks prior to study entry.
We found this trial at
14
sites
Weston, Florida 33331
?
mi
from
Weston, FL
Click here to add this to my saved trials
9500 Euclid Avenue
Cleveland, Ohio 44106
216.444.2200
Phone: 800-270-3165
Cleveland Clinic Cleveland Clinic is committed to principles as presented in the United Nations Global...
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
4200 Fifth Ave
Pittsburgh, Pennsylvania 15260
(412) 624-4141
University of Pittsburgh The University of Pittsburgh is a state-related research university, founded as the...
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
?
mi
from
Decatur, IL
Click here to add this to my saved trials
Effingham, Illinois 62401
?
mi
from
Effingham, IL
Click here to add this to my saved trials
400 Oxford Drive
Monroeville, Pennsylvania 15146
?
mi
from
Monroeville, PA
Click here to add this to my saved trials
Morgantown, West Virginia 26506
(304) 293-0111
Phone: 800-270-3165
West Virginia University West Virginia University, founded in 1867, has a long and rich history...
?
mi
from
Morgantown, WV
Click here to add this to my saved trials
800 Northeast 10th Street
Oklahoma City, Oklahoma 73104
?
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
300 Halket St.
Pittsburgh, Pennsylvania 15213
1-866-MyMagee (696-2433)
Phone: 800-270-3165
Magee-Womens Hospital of UPMC Magee-Womens Hospital of UPMC is a world-class center for both women's...
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Pittsburgh, Pennsylvania 15212
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Pittsburgh, Pennsylvania 15232
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Pittsburgh, Pennsylvania 15215
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
101 Dudley St
Providence, Rhode Island 02905
(401) 274-1100
Phone: 800-270-3165
Women and Infants Hospital of Rhode Island Women & Infants Hospital of Rhode Island, a...
?
mi
from
Providence, RI
Click here to add this to my saved trials
13 Wolf Creek Drive
Swansea, Illinois 62226
?
mi
from
Swansea, IL
Click here to add this to my saved trials